233 related articles for article (PubMed ID: 27321312)
1. Which oral antidiabetic drug to combine with metformin to minimize the risk of hypoglycemia when initiating basal insulin?: A randomized controlled trial of a DPP4 inhibitor versus insulin secretagogues.
Gautier JF; Monguillon P; Verier-Mine O; Valensi P; Fiquet B; Dejager S; Charbonnel B
Diabetes Res Clin Pract; 2016 Jun; 116():26-8. PubMed ID: 27321312
[TBL] [Abstract][Full Text] [Related]
2. Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus.
Ning G; Wang W; Li L; Ma J; Lv X; Yang M; Wang W; Woloschak M; Lukashevich V; Kothny W
J Diabetes; 2016 May; 8(3):345-53. PubMed ID: 25929739
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
Lukashevich V; Del Prato S; Araga M; Kothny W
Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686
[TBL] [Abstract][Full Text] [Related]
4. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
Derosa G; Bonaventura A; Bianchi L; Romano D; Fogari E; D'Angelo A; Maffioli P
Metabolism; 2014 Jul; 63(7):957-67. PubMed ID: 24874591
[TBL] [Abstract][Full Text] [Related]
5. Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin.
Schweizer A; Foley JE; Kothny W; Ahrén B
Vasc Health Risk Manag; 2013; 9():57-64. PubMed ID: 23431062
[TBL] [Abstract][Full Text] [Related]
6. Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database.
Detournay B; Halimi S; Robert J; Deschaseaux C; Dejager S
Vasc Health Risk Manag; 2015; 11():417-25. PubMed ID: 26229480
[TBL] [Abstract][Full Text] [Related]
7. Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea.
Xiaoyan C; Jing W; Xiaochun H; Yuyu T; Shunyou D; Yingyu F
Curr Med Res Opin; 2016 Jun; 32(6):1131-6. PubMed ID: 26950829
[TBL] [Abstract][Full Text] [Related]
8. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
Göke R; Gruenberger JB; Bader G; Dworak M
Curr Med Res Opin; 2014 May; 30(5):785-9. PubMed ID: 24328429
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment.
Lukashevich V; Schweizer A; Foley JE; Dickinson S; Groop PH; Kothny W
Vasc Health Risk Manag; 2013; 9():21-8. PubMed ID: 23378769
[TBL] [Abstract][Full Text] [Related]
10. Treatment with metformin and a dipeptidyl peptidase-4 inhibitor elevates apelin levels in patients with type 2 diabetes mellitus.
Fan Y; Zhang Y; Li X; Zheng H; Song Y; Zhang N; Shen C; Fan X; Ren F; Shen J; Ren G; Yang J
Drug Des Devel Ther; 2015; 9():4679-83. PubMed ID: 26316706
[TBL] [Abstract][Full Text] [Related]
11. A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study.
Hassanein M; Abdallah K; Schweizer A
Vasc Health Risk Manag; 2014; 10():319-26. PubMed ID: 24920915
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION).
Ji LN; Pan CY; Lu JM; Li H; Zhu DL; Li Q; Li QF; Peng YD; Tian HM; Yao C; Zhao ZG; Wang L; Wang BH;
Diabetes Obes Metab; 2016 Aug; 18(8):775-82. PubMed ID: 27406394
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus.
Kim G; Oh S; Jin SM; Hur KY; Kim JH; Lee MK
Expert Opin Pharmacother; 2017 Aug; 18(12):1179-1186. PubMed ID: 28714741
[TBL] [Abstract][Full Text] [Related]
14. Differences in glycemic control across world regions: a post-hoc analysis in patients with type 2 diabetes mellitus on dual antidiabetes drug therapy.
Brath H; Paldánius PM; Bader G; Kolaczynski WM; Nilsson PM
Nutr Diabetes; 2016 Jul; 6(7):e217. PubMed ID: 27376699
[TBL] [Abstract][Full Text] [Related]
15. Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus - results from an exploratory study.
Berndt-Zipfel C; Michelson G; Dworak M; Mitry M; Löffler A; Pfützner A; Forst T
Cardiovasc Diabetol; 2013 Apr; 12():59. PubMed ID: 23565740
[TBL] [Abstract][Full Text] [Related]
16. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Mikhail N
Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
[TBL] [Abstract][Full Text] [Related]
17. Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus.
Yang W; Xing X; Lv X; Li Y; Ma J; Yuan G; Sun F; Wang W; Woloschak M; Lukashevich V; Kozlovski P; Kothny W;
J Diabetes; 2015 Mar; 7(2):174-81. PubMed ID: 24823599
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of vildagliptin as add-on to metformin monotherapy among uncontrolled type 2 diabetes mellitus patients in a real-world setting.
Melzer Cohen C; Davis C; Shalev V; Chodick G
J Diabetes; 2018 Jan; 10(1):68-72. PubMed ID: 28418203
[TBL] [Abstract][Full Text] [Related]
19. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
Schweizer A; Dejager S; Bosi E
Diabetes Obes Metab; 2009 Aug; 11(8):804-12. PubMed ID: 19476473
[TBL] [Abstract][Full Text] [Related]
20. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus.
Fonseca V; Baron M; Shao Q; Dejager S
Horm Metab Res; 2008 Jun; 40(6):427-30. PubMed ID: 18401832
[No Abstract] [Full Text] [Related]
[Next] [New Search]